Pemphigus Vulgaris Treatment Market - Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Pemphigus vulgaris is an autoimmune disorder in which painful blisters are formed on the mucus membrane and skin. The disorder is rare and affects mouth, nose, throat, lungs, eyes, and sometimes genitals. The disorder is caused when the body produces antibodies against self-cells, although the exact cause and mechanism is unknown. Formation of Immunoglobulin G (IgG) antibodies against self desmosomal adhesion proteins, present on epidermal keratinocytes, results in blister formation. Its diagnosis involves biopsy (tissue sampling), blood tests for pemphigus specific antibodies, and endoscopy. The treatment involves administration of immunosuppressant drugs and corticosteroids. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2530 Pemphigus Vulgaris Treatment Market Drivers New drug approvals is expected to drive the global pemphigus vulgaris treatment market growth over the forecast period. For instance, in June 2018, the U.S. Food and Drug Administration (FDA) approved the use of Rituximab for the treatment of pemphigus vulgaris. Rituximab is a humanized anti-cd20 monoclonal antibody and acts to reduce the number of skin lesions. The drug acts by targeting cd20 antigen, expressed on cells of B cell lineage and kills B cells. Rituximab acts by inhibiting cell proliferation and inducing cell apoptosis. Rituximab has minimal immunogenicity and can be reused. Pemphigus Vulgaris Treatment Market Regional Analysis Government agencies are indulged in research and development of new drugs for pemphigus vulgaris treatment. For instance, National Institute of Allergy and Infectious Diseases (NIAID), an agency of the U.S. Department of Health and Human Services (HHS), is conducting a Phase 1 trial to check use of Polyclonal T regulatory cells in treatment of pemphigus vulgaris. The study started in September 2017, and is estimated to be completed by September 2020. Therefore, active research and development by key players in the region is expected to support North America pemphigus vulgaris treatment market growth over the forecast period. Report includes chapters which deeply display the following deliverable about industry : • Pemphigus Vulgaris Treatment Market Research Objective and Assumption • Pemphigus Vulgaris Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Pemphigus Vulgaris Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Pemphigus Vulgaris Treatment Market, By Regions • Pemphigus Vulgaris Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Pemphigus Vulgaris Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Pemphigus Vulgaris Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Pemphigus Vulgaris Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Pemphigus Vulgaris Treatment Market Key Players Some of the key players operating in the global pemphigus vulgaris treatment market include, Principia Biopharma, Argenx SE, Alexion Inc., Genentech, Inc., Novartis International AG, GlaxoSmithKline plc. Vifor Pharma Management Ltd., and F. Hoffmann-La Roche AG Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2530 Pemphigus Vulgaris Treatment Market Taxonomy The global pemphigus vulgaris treatment market is segmented on the basis of drugs route of administration, distribution channel, and region. By Drugs Azathioprine Rituximab Cyclophosphamide Cyclosporine Pipeline drugs • PRN1008 • Others • • • • • By Route of Administration • Oral • Injectable By Distribution Channel • Hospital pharmacies • Retail pharmacies • Online pharmacies By Region • • • • • • North America Latin America Europe Asia Pacific Middle East Africa About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
© Copyright 2024 Paperzz
